Improvement of cutaneous inflammation and panniculitis in patients with dermatomyositis by the Janus kinase inhibitor baricitinib.

Szczegóły

Tytuł :: Improvement of cutaneous inflammation and panniculitis in patients with dermatomyositis by the Janus kinase inhibitor baricitinib.
Autorzy :: Fischer K; Department of Dermatology Medical Faculty Carl Gustav Carus, Technical University Dresden, Dresden, Germany.
Aringer M; Department of Medicine III, Rheumatology; Medical Faculty Carl Gustav Carus, Technical University Dresden, Dresden, Germany.
Steininger J; Department of Dermatology Medical Faculty Carl Gustav Carus, Technical University Dresden, Dresden, Germany.
Heil J; Department of Dermatology Medical Faculty Carl Gustav Carus, Technical University Dresden, Dresden, Germany.
Beissert S; Department of Dermatology Medical Faculty Carl Gustav Carus, Technical University Dresden, Dresden, Germany.
Abraham S; Department of Dermatology Medical Faculty Carl Gustav Carus, Technical University Dresden, Dresden, Germany.
Günther C; Department of Dermatology Medical Faculty Carl Gustav Carus, Technical University Dresden, Dresden, Germany.; Pokaż więcej
Źródło :: The British journal of dermatology [Br J Dermatol] 2022 Mar 23. Date of Electronic Publication: 2022 Mar 23.
Publication Model :: Ahead of Print
Typ publikacji :: Letter
Język :: English
Imprint Name(s) :: Publication: Oxford : Blackwell Scientific Publications
Original Publication: Oxford [etc.] Published for the British Association of Dermatologists by Blackwell Scientific Publications [etc.]
References :: Baechler EC, Bilgic H, Reed AM. Type I interferon pathway in adult and juvenile dermatomyositis. Arthritis Res Ther 2011; 13:249.
Delvino P, Bartoletti A, Monti S et al. Successful treatment with baricitinib in a patient with refractory cutaneous dermatomyositis. Rheumatology (Oxford) 2020; 59:4003.
Papadopoulou C, Hong Y, Omoyinmi E et al. Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis. Brain 2019; 142:e8.
Kim H, Dill S, O’Brien M et al. Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis. Ann Rheum Dis 2021; 80:406-8. https://doi.org/10.1136/annrheumdis-2020-218690.
Chen D, Huang W, Wang Z et al. Good efficacy achieved by baricitinib in the treatment of anti-MDA5 antibody-positive dermatomyositis with alopecia areata. Rheumatology (Oxford) 2022; in press; doi:https://doi.org/10.1093/rheumatology/keac084.
Le Voyer T, Gitiaux C, Authier FJ et al. JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study. Rheumatology (Oxford) 2021; 60:5801-8.
Heinen A, Schnabel A, Brück N et al. Interferon signature guiding therapeutic decision making: should ruxolitinib be considered as first-line therapy for severe juvenile dermatomyositis? Rheumatology (Oxford) 2021; 60:e136-8. https://doi.org/10.1093/rheumatology/keaa657.
Santos-Briz A, Calle A, Linos K et al. Dermatomyositis panniculitis: a clinicopathological and immunohistochemical study of 18 cases. J Eur Acad Dermatol Venereol 2018; 32:1352-9.
Grant Information :: KFO 249/GU1212/1-1 Deutsche Forschungsgemeinschaft; KFO 249/GU1212/1-2 Deutsche Forschungsgemeinschaft; TRR237 369799452/404458960 Deutsche Forschungsgemeinschaft; MEDDRIVE Medical Faculty, Technical University Dresden; Roche research award Roche
Entry Date(s) :: Date Created: 20220323 Latest Revision: 20220520
Update Code :: 20220525
DOI :: 10.1111/bjd.21252
PMID :: 35318646
: Opinia redakcyjna

Full Text Finder

Informacja

Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu